Design Therapeutics (DSGN) Other Gross PP&E Adjustments (2020 - 2026)
Design Therapeutics recorded quarterly Other Gross PP&E Adjustments of $676000.0 in Q1 2026, up 133.75% quarter-over-quarter from -$2.0 million in Q4 2025, and down 41.37% year-over-year from $1.2 million in Q1 2025.
Design Therapeutics' Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at $676000.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments fell 41.37% year-over-year to $676000.0; the TTM figure through Mar 2026 stood at $676000.0 (down 41.37% YoY), while the FY2025 annual figure was -$2.0 million, up 34.52% from the prior year.
- Other Gross PP&E Adjustments came in at $676000.0 for Q1 2026 at Design Therapeutics, up from -$2.0 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $1.6 million in Q3 2025 to a low of -$3.4 million in Q4 2023.
- A 5-year average of -$731235.3 and a median of -$635000.0 in 2023 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments sank 1785.32% in 2022 and soared 629.75% in 2025, its largest moves.
- Design Therapeutics' Other Gross PP&E Adjustments stood at -$2.9 million in 2022, then retreated by 19.42% to -$3.4 million in 2023, then increased by 11.15% to -$3.1 million in 2024, then surged by 34.52% to -$2.0 million in 2025, then soared by 133.75% to $676000.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered $676000.0, -$2.0 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 676,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676,000.00 |
| Mar 31, 2026 | 676,000.00 |
| Dec 31, 2025 | -2.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | -3.06 Mn |
| Dec 31, 2024 | -3.06 Mn |
| Sep 30, 2024 | 664,000.00 |
| Sep 30, 2024 | 664,000.00 |
| Jun 30, 2024 | 498,000.00 |
| Jun 30, 2024 | 498,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Dec 31, 2023 | -3.44 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -412,000.00 |
| Sep 30, 2023 | -412,000.00 |
| Jun 30, 2023 | -635,000.00 |
| Jun 30, 2023 | -635,000.00 |
| Mar 31, 2023 | -891,000.00 |
| Mar 31, 2023 | -891,000.00 |
| Dec 31, 2022 | -2.88 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.84 Mn |
| Jun 30, 2022 | -1.84 Mn |
| Mar 31, 2022 | -1.84 Mn |
| Mar 31, 2022 | -1.84 Mn |
| Dec 31, 2021 | -2.50 Mn |
| Dec 31, 2021 | -2.50 Mn |
| Sep 30, 2021 | -2.37 Mn |
| Sep 30, 2021 | -2.37 Mn |
| Jun 30, 2021 | 292,000.00 |
| Jun 30, 2021 | 292,000.00 |
| Mar 31, 2021 | 109,000.00 |
| Mar 31, 2021 | 109,000.00 |
| Dec 31, 2020 | 51,000.00 |
| Dec 31, 2020 | 51,000.00 |